Countries
Industry
Startup stage
Startup size
Funding
Impact startup SDGs
Showing: 7845 filtered startups

CHOOOSE

CHOOOSE is a climate-focused technology company in Oslo, Norway. With a mission to accelerate the shift towards a sustainable future, CHOOOSE delivers a platform that enables both individuals and organizations to connect with the best CO2-reducing projects around the world. CHOOOSE supports individuals and organizations in over 70 countries. CHOOOSE partners with thoughtful consumer brands across verticals to integrate carbon offsetting into their products, services, and operations - all through a positive, action-first lens. Powering the CHOOOSE Platform is a curated portfolio of CO2-reducing projects from which partners can select to execute their offsetting. All projects are certified by the International Gold Standard and continually monitored by the CHOOOSE network of carbon professionals. www.chooose.today

Meru Health

Meru Health is an online medical clinic treating depression.We envision a world in which all people have the tools they need to overcome depression.We are scientists, engineers and experienced entrepreneurs who have come together to make depression treatment accessible, effective and truly outcome-driven. Our mission is more than business, it’s personal. Our founders have lost friends and family members to depression, and we want to do everything in our power to help people who suffer. We are scientists, engineers and experienced entrepreneurs with a big vision to make mental healthcare accessible, engaging and outcome driven. We want to help humanity become more empowered and happy. We are people with strong and sound value base, and when Meru Health was founded, we wanted to incorporate our values to become the company’s values as well.

Ellen Testing Archiving Feature

I*m just testing the archiving feature. I*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving featureI*m just testing the archiving feature

Cucumber GoGo

Tools & techniques that elevate teams to greatness It’s simple. Whether open source or commercial, our collaboration tools will boost your engineering team's performance by employing Behavior-Driven Development (BDD). And with our world-class training, take it to places it’s never been.

LINKAI Technologies AB

We develop B2B privacy-preserving AI solutions to inspection, testing and certification of critical systems to empower smart manufacturing in Sweden, and the Nordics. We provide AI-driven solutions to help companies reduce cost and project development lifecycle, improve result accuracy, define and implement making-sense AI strategies while guaranteeing customer data privacy, data access and information security. As an early-stage startup, we have been engaged in pilot projects with enterprise users/prospects from the aerospace, pipeline transport and utilities sectors. Currently, our top-line offerings include: 1) Privacy-preserving AI-driven domain-specific visual inspection solutions to PCB and welding defect detection 2) A proprietary integrated solution to the continuous AI learning and improvement without using manufacturing data 3) Add-on features such as remote expert consultation from within the inspection software when a second opinion adds value, and an automated reporting system/tool with detailed and convenient documentation. Part of our development has been supported by Vinnova since Nov. 2020, and welcome to get connected with/follow us via LinkedIn, and/or reach out to us via info@linkaitech.eu for an interesting discussion and/or a demo. We are highly interested in building up a bank of potential candidates, therefore, feel free to send us your open application, tell us what you have got to offer to stay relevant for a next trillion-dollar industry, via jobs@linkaitech.eu. At LinkAI, we inspect and test different, and we are linking AI / 愛.

Xilium A/S

Xilium is a software and consultancy company that has specialized in providing clinical decision support and regulatory compliant software to handle healthcare communication between medical professionals and patients. To be a bit more specific, we develop and market the product, DizzyGuide. In basic terms, DizzyGuide is a patient questionnaire (for patients with dizziness symptoms) that, once answers have been processed by the algorithm, will provide healthcare professionals with guidance to ensure the shortest and best patient journey through the healthcare system. The questionnaire and algorithm which our software is based on were initially developed by experts at Mayo Clinic, The number 1 hospital in the World. Today, the development of the questionnaire and algorithm is continued in collaboration between members of our advisory board: Xilium, Mayo Clinic, Michigan Medicine, and the University of Lund, in Sweden. NOTE. we are in the process of changing our name. Therefore the link to our old website.

GetAccept

Founded in 2015 by experienced entrepreneurs, we quickly gained traction as a Y Combinator funded Company – one of the most prestigious startup-accelerators in the world. Since then, we have grown from a Startup-challenger to becoming an industry leader within our area. GetAccept is an All-in-One Platform for B2B Sales and our Vision is to become the platform where every B2B business happens, in a natural way. We just raised 120Million to rock on - wanna dance?

Frejac

We aim to develop evidence-based mindfulness tools and community for professional females to grow with joy and fulfillment. Many professional females face similar situations where they achieve a lot but feeling not fulfilled. We want to distill the technologies behind mindfulness and inspire females to develop with their own flow

Mendonca Biomed

Mendonca Biomed is an early stage life science startup with the aim to develop and validate novel biomarker for the early detection of viral infections in blood with an affordable yet simple detection method that can be universally applied. The company was originally founded by myself Kevin Mendonca in India based on his 15 years of accumulative research knowledge. Preliminary data on the utility of viral miRNA biomarkers for the screening of blood for transfusion transmitted viral infections, which are potentially superior to the currently available markers, and a simplified assay that is cost effective and can be universally adapted, were developed in India. However, due to an innate lack of infrastructure and funding opportunities in India, I applied for the startup Denmark program to move the company to the medicon valley. I recently moved to Demark, registered a privately owned company and currently in pursue of funding to validate the viral miRNA biomarkers for the early detection of HIV, HBV and HCV in donated blood. Around the world, more than 92 million blood donations are collected every year. Screening of donated blood and derived products, for HIV, HBV and HCV is mandatory worldwide. Screening is a key safety measure in protecting recipients from transfusion transmitted infections, especially in developing nations in Africa and Asia, where the donated blood is not processed because of high costs and lack of infrastructure. Moreover, in emergency situation like natural calamities, disasters and sudden outbreaks, the currently available methods are inadequate for on-site screening. Serological testing (antigen and antibody detection assays) have historically been the foundation of blood screening but with huge drawbacks of long window periods. Newer strategies like the PCR based amplification viral genomic DNA/RNA in blood have helped shorten the window period but have not eliminated it. PCR assays have also been known to fail in low viremia and/or suboptimal amplification efficiency. They are far more expensive than the serological assay, requires expertise, specialized equipment and a molecular biology setup, which is not available in the resource poor settings of the developing countries. Our solution is to develop and validate novel viral miRNA biomarkers that have the potential to further reduce the window period and use the unique characteristics of these biomarkers to develop a simple, multiplex (3 in 1), inexpensive probe hybridization assay that can be universally utilized in all settings and conditions. Viral miRNA molecules are easy to validate as biomarkers since the presence of vmiRNA’s is a definite indicator of infected cells. Benefit: Multiplex 3 in 1 test. Method as simple to perform as the serological assay with the benefits of a molecular assay. Can be adapted in any setting, even in the field and low resource conditions in developing nations. Potentially, lower window period of detection compared to any biomarkers that are available in the market currently. Value: High throughput, lower turnover time with lower chances of human error. Advantages of a molecular assay with the simplicity and affordability of a serological assay. Does not require specialized setup, infrastructure and highly trained technicians. Potentially, could detect the infections faster than any other tests in the market, lowering the risk of transfusion transmission. Once this platform has been validated, the product line can be expanded to cover all commercially viable viral infections. A HPV assay based on this platform, for example, could be a potential replacement for the invasive PAP test, and can be performed during a routine blood test. The platform can be further adapted to screen for novel viral infections like SARS, MERS, ZIKA etc. It can be also be developed to screen and control other sporadic outbreaks the like Dengue, Chikungunya etc.

NornGuest Ventures

NornGuest Ventures are currently working on a start up in cooperation with Barut Ren ApS. The start up is yet to be named, but essentially we are about to be producing furnitures of danish design from recycled plastic waste. The machinery is under construction and we expect to start production by March 21' We are looking for sales and marketing interns to help us plan and execute a sales and markerting campaign. The startup is on a very early stage, and the interns will get a lot of responsibility and opportunity to help shape the development of the brand,

Unistu Consulting

As a consultancy of young and passionated students, we are working every day to unleash the innovation potential of our nation's firms and organisations. We believe our nation should be an international innovation center with a flourishing business life. Therefore, we work towards bringing innovation faster, more flexible and cheeper to our clients. We deliver value by asking deep, fundamental questions and challenging business-as-usual. Our tailor-made project teams consists of highly driven students from different fields of study and together they combine the very best of each individual team member. Our business is grounded in a deep belief in the youth. We believe that young people deserve an opportunity to use their knowledge and creativity to drive real impact for firms, organisations and society as a whole.

My Personal Health Bank

For a quick intro pls see: https://drive.google.com/file/d/168TTZsNef43Awmxz3iALMhx2saVk5ihe/view?usp=sharing The problem & the idea Data may be the driver for change, improvement and understanding, in many sectors, amongst these also healthcare. Patient data is an important creator of knowledge both on an individual level but also on a group, regional or country level. On an individual level, patient data may support and build the clinical decisions, it may provide more efficient treatment, both in regard to time and economy and secure that knowledge about the individual is transferred fast and unbiased to the healthcare staff. For the patient, sharing of his/her data will secure a better understanding of the needs and support better diagnosis and treatment. Patient data are collected and noticed in some form in most countries, either on paper or electronically. Many countries have some sort of an electronic patient journal, either on a country level, regionally or locally. However, many countries also still use pen & paper. This challenges the storage and continuity of data collection and transfer. Patient data records in electronic form reduces the risk of losing valuable data but also allows the data to be shared if needed. The acknowledgement of the importance on several levels of having patient data and the absence of a central, regional or local electronic patient data recording system in Sub-saharan African countries (the target region) initiated the idea of looking at how it would be possible to collect and make patient data readily available for treatment, benefitting both patient and caregiver, and in a bigger perspective, for research and strategic healthcare initiative planning. During small initial market and possibility investigations the idea of creating a patient owned electronic healthdata journal app arose. Mobiletechnology is both greatly advantaged and outspread in the target region and the number of mobile consumers are increasing every year. It was and is anticipated, that the possibility of having a central system is, due to structural and financial reasons, not a possibility but to empower the patient with the ownership of own data through an app seemed a possibility. It is important to underline that data must be generated from the healthcare provider and then fed into the patientjournal at the site of the consultation. The idea is to have the most relevant data collected and stored in the app, ie. medication, allergies, blood type, diagnosis and immunizations. The data that will go into the app is transferred from a healthcare provider at the site of the healthcare visit, eg a clinique, hospital, other. That means that the healthcare provider must have access to a tablet or smartphone containing the healthcare provider app which connects to the patients healthcare data app at the visit. Also any healthcare provider with the app will followingly get access to the data from the patient by connecting (and by being given access by the patient) to get patients healthdata app. So, in summary the basic idea is to provide all citizens with a tool that will help them keep track of their most important healthcare related data including completed and planned treatments, diagnosis, tests, allergies etc. The idea is further that the data is owned by the citizens/patients, and not by the non-existing national or any hospital specific system. Upon each contact with the healthcare personnel the patient's information is updated by the healthcare personnel (e.g. symptoms, diagnosis, tests, treatment, next visit etc.) The basic idea/assumption is that no national healthcare system will be developed in near or short-term future, and that a personally owned "electronic patient journal" can have a significant positive impact on the quality of treatments because of a more complete picture of the patient is available at the time, when a diagnosis and treatment is to be decided.

Ceretai

Ceretai develops AI software and services to help the media and entertainment industries improve diversity and equality in TV programs, movies and other media content. In the Western world we consume up to 10 hours of media every day - news, Netflix, social media, you name it. Through this media we are shown a biased image of the world - for example, only 30% of speaking roles in cinema movies globally are given to women, and only 1% of characters in movies have functional limitations. This of course affects our view of the world, teaching us biases and contributing to an unsustainable world of discrimination and segregation. At the same time, national and international governmental bodies in the media industry are focusing very hard on exactly these issues. Just like in other industries, authorities like the European Broadcasting Union and national public service regulators are looking at the UN sustainability goals and trying to find ways to increased gender equality (goal no. 5) and decreased inequalitites (goal no. 10). Research shows that 80% of movie and TV audiences want to change the state of diversity in media and entertainment. "Newcomers" like Netflix continue to steal audiences with norm-breaking series showing a different picture of the world - one that includes a diversity of stories and people. At Ceretai we have made it our mission to support the media industry in creating more diversity in their content. We have built a SaaS solution, the Diversity Dashboard, that automatically analyses any given media file for gender and age representation, and we continue to develop it to cover more grounds for discrimination. We also provide services for creating awareness and fostering change within European media organisations, for example workshops and reports. The idea that became Ceretai was sparked in late 2017, in the wake of the Me Too campaign, when the founders grew tired of not finding entertainment that matched their values. Realising how unconsciously biased we all are, the company was founded in early 2018 with the idea of building an automated tool for detecting norms and stereotypes in popular culture. Our mission has stayed the same: contributing to a more equal and tolerant world by using technology to create awareness and change.

Mads Olesen Holdings

Mads Olesen Holdings is owned by entrepreneur Mads Andreas Olesen. After selling his first companies for more than 100 mio. kroner, he now invests in startups, real estate and more through Mads Olesen Holdings (CVR: 36917997) and subsidiaries. In 2020, Mads Olesen Holdings invested in more than 50 ecommerce businesses through its investment in MXNEY.io, that specializes in alternative ecommerce funding. In 2021, the holding company is looking to add 10 properties to its current portfolio of 19 rental properties.

Metaceutic

Our mission is to provide functionally validated, personalised healthcare solutions to address unmet needs within cognitive disorders and obesity. Our journey is part of a healthcare evolution away from symptom-based, one-fits-all medicine, and towards personalised, causality-driven solutions with systemic efficacy - with the aim to address major global disease challenges in a more targeted, natural manner. Metaceutic ApS develops plant-based health-enhancing dietary food supplements that are functionally validated to predictably alter specific parts of the gut microbiota in order to enhance cognitive function regarding mental stress remedy, appetite regulation, and general cognitive enhancement.